Company intelligence / Profile preview

Talon Therapeutics

South San Francisco, California, United Statestalonpharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Talon Therapeutics developed Marqibo® (vincristine sulfate liposome injection) for adult Philadelphia chromosome-negative ALL in second or greater relapse. The company also pursued small molecule and CNS-targeted therapies but these did not advance beyond early clinical stages before the company was acquired by Spectrum Pharmaceuticals in 2013.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculesliposomal drug formulations
Industry: Biotech

Beyond the preview

Go deeper on Talon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talon Therapeutics.

Explore the full profile